Caitong International Asset Management Co., LTD Bei Gene, Ltd. Transaction History
Caitong International Asset Management Co., LTD
- $134 Billion
- Q1 2025
A detailed history of Caitong International Asset Management Co., LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 318 shares of BGNE stock, worth $72,093. This represents 0.06% of its overall portfolio holdings.
Number of Shares
318
Previous 4
7850.0%
Holding current value
$72,093
Previous $739,000
11611.77%
% of portfolio
0.06%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
275Shares Held
41.6MCall Options Held
106KPut Options Held
81.6K-
Baker Bros. Advisors LP New York, NY9.53MShares$2.16 Billion19.52% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.8MShares$862 Million26.88% of portfolio
-
Baillie Gifford & CO3.63MShares$823 Million0.74% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...